#EchoGo
LightNews LightNews
simonb72.bsky.social
This is a definite upgrade to the more standard Japanese lagers in these parts
Koshihikari Echogo beer
October 14, 2025 at 11:36 PM
ultromics.com
EchoGo® Amyloidosis is the first AI screening tool to help detect Cardiac #Amyloidosis using #EchoFirst. Seamlessly integrating into clinical workflows, it supports timely identification and intervention. 👉 www.ultromics.com/products/ech... #MedSky #CardioSky
January 28, 2025 at 4:08 PM
ultromics.com
EchoGo® Heart Failure was developed with Mayo Clinic.
Patricia A. Pellikka, MD shares her views on the impact of our AI platform in detecting heart failure patients. Learn more about how EchoGo® Heart Failure supports #HeartFailure detection: www.ultromics.com/products/ech... #CardioSky #MedSky
January 31, 2025 at 6:05 PM
ultromics.com
We’ll be at THT in 3 weeks, we're excited to discuss EchoGo® Heart Failure, 0ur AI-powered tool that helps detect #HFpEF & Cardiac #Amyloidosis from a routine echocardiogram. Meet us to learn how EchoGo® is transforming #HeartFailure care. www.ultromics.com/about/events #MedSky #CardioSky
January 22, 2025 at 11:42 AM
americanheartj.bsky.social
Open Access: PROTEUS Study: A Prospective Randomized Controlled Trial Evaluating the Use of Artificial Intelligence in Stress Echocardiography. pubmed.ncbi.nlm.nih.gov/37192698/

#CardioSky #Cardiology
Background: Stress echocardiography (SE) is one of the most commonly used diagnostic imaging tests for coronary artery disease (CAD) but requires clinicians to visually assess scans to identify patients who may benefit from invasive investigation and treatment. EchoGo Pro provides an automated interpretation of SE based on artificial intelligence (AI) image analysis. In reader studies, use of EchoGo Pro when making clinical decisions improves diagnostic accuracy and confidence. Prospective evaluation in real world practice is now important to understand the impact of EchoGo Pro on the patient pathway and outcome. More here: https://www.sciencedirect.com/science/article/pii/S000287032300114X?via%3Dihub Table I. PROTEUS trial objectives and outcome measures More here: https://www.sciencedirect.com/science/article/pii/S000287032300114X?via%3Dihub#tbl0001 Figure 1. PROTEUS Study overview and visit schedule. Provides an overview of the study, describing the inclusion/exclusion criteria, randomization arms, and study visits. More here: https://www.sciencedirect.com/science/article/pii/S000287032300114X?via%3Dihub#fig0001
September 23, 2023 at 4:31 PM
ultromics.com

We’re excited to share our latest research & innovation at several events this year. Ultromics is transforming cardiology with advanced AI that supports #HFpEF and Cardiac #Amyloidosis detection. Upcoming events: www.ultromics.com/about/events #EchoGo #MedSky #CardioSky
January 14, 2025 at 2:21 PM
ultromics.com
EchoGo® Heart Failure is eligible for reimbursement in both inpatient & outpatient settings & includes
#HFpEF & Cardiac Amyloidosis detection to aid care in #HeartFailure.

💰 Inpatient: NTAP XXE2X19 – Up to $1,023.75
💰 Outpatient: CPT 0932T – $299.91

👉https://www.ultromics.com/about/reimbursement
January 8, 2025 at 4:12 PM
ultromics.com
Detecting HFpEF early is critical so patients can benefit from these innovative treatments. #SGLT2 inhibitors are a breakthrough treatment for HFpEF. However, many patients are undiagnosed. EchoGo® Heart Failure uses advanced AI to detect #HFpEF from a single routine echo. Learn more: ultromics.com
accintouch.bsky.social American College of Cardiology @accintouch.bsky.social · Jan 7
#SGLT2 inhibitors are key in preventing adverse CV events & improving outcomes in patients w/ heart failure, diabetes & chronic kidney disease. Explore the updated #CardioSmart SGLT2 inhibitor package w/ an infographic, discussion guide, & more. bit.ly/3PssDFq

#CardioSky #MedSky
January 10, 2025 at 1:43 PM
drtimos.bsky.social
LucidQuest YouTube > Trending in Women’s Health: AI HFpEF, SLE pen, RRMS, HER2 and more: Women’s Health highlights: AHA’s fund backs Ultromics’ EchoGo HFpEF AI. EU approves subcutaneous Saphnelo for at-home SLE use. NICE recommends natalizumab, including… Subscribe for more! #LucidQuest #PharmaCI
Trending in Women’s Health: AI HFpEF, SLE pen, RRMS, HER2 and more
Women’s Health highlights: AHA’s fund backs Ultromics’ EchoGo HFpEF AI. EU approves subcutaneous Saphnelo for at-home SLE use. NICE recommends natalizumab, including biosimilar, for highly active RRMS when cladribine is unsuitable. FDA issues a CRL to tolebrutinib in non-relapsing SPMS. BHV-7000 fails Phase 2 in MDD. AXS-05 for Alzheimer’s agitation gets Priority Review, PDUFA April 30, 2026. Thermo Fisher initiates CorEvitas Alzheimer’s registry. PIPE-307 misses RRMS remyelination endpoint. China adds 13 percent VAT to contraceptives. FDA approves Enhertu plus pertuzumab first-line in HER2-positive breast cancer.
www.youtube.com
January 7, 2026 at 1:31 PM
newsen.bsky.social
AI Technology in Cardiovascular Care: Better Diagnosis of Heart Failure with Ultromics' EchoGo® System#United_Kingdom#Oxford#Heart_Failure#Ultromics#EchoGo
AI Technology in Cardiovascular Care: Better Diagnosis of Heart Failure with Ultromics' EchoGo® System
The American Heart Association reports that Ultromics' EchoGo® Heart Failure could diagnose HFpEF earlier, potentially saving lives and healthcare costs.
third-news.com
July 22, 2026 at 11:19 AM
l2plabs.bsky.social
American Heart Association AI Assessment Lab Report Finds Ultromics' EchoGo® Heart Failure May Identify HFpEF Earlier Than Standard Care
Powered by retrospective real-world data from Dandelion Health, the American Heart Association's AI Impact Report provides a third-party evaluation of Ultromics' EchoGo® Heart Failure The independent assessment shows EchoGo® Heart Failure could have identified HFpEF 263 days earlier than...
dlvr.it
July 22, 2026 at 11:03 AM
ase360.bsky.social
Industry Sponsored Message: Learn how leaders from Mayo Clinic, University of Chicago Medicine and City of Hope are integrating Ultromics EchoGo® into their clinical workflows to support the detection of HFpEF and cardiac amyloidosis.

Watch the webinar on our ASE Learning Hub: bit.ly/4nu6ndm
September 30, 2025 at 3:50 PM
averagedoc.bsky.social
Asked a nurse today if the patient had an echo done, she said yah, and added definitevly, 67%. I think we can switch to 5 minute scans and no one would notice. Just get 3 apicals, plax and ivc. Send it to echogo for AI diastology. Plax color rules out bad valve disease. Crushed it. #cardiosky
September 7, 2025 at 4:59 PM
vanuatutech.bsky.social
#TechNews #TechTips
Oxford-based Ultromics, which has developed the first FDA-cleared, Medicare-reimbursed AI tools for cardiology diagnostics, raised a $55M Series C (Tamara Djurickovic/Tech.eu)
Tamara Djurickovic / Tech.eu: Oxford-based Ultromics, which has developed the first FDA-cleared, Medicare-reimbursed AI tools for cardiology diagnostics, raised a $55M Series C  —  The funding will accelerate Ultromics' mission to advance heart disease detection and scale EchoGo®, its AI platform for earlier, more accurate diagnoses.
www.techmeme.com
July 31, 2025 at 11:15 AM
chidambara09.bsky.social
cardiovascularbusiness.com/topics/clini...
@enilev.bsky.social
my enilev🪔mom

🌐 #BOSCh
@bsky.app #blueSky
#bigdata #MachineLearning
#CyberSecurity #Crypto #Technology #uk #bitcoin #Digital #genAI #ai #eUrope #frenchTECh #Linkedin #HealthTech #DiGiTALhealth #USA #Quantum #Health #web3 #SOciaLmeDia
FDA clears AI screening tool for cardiac amyloidosis
Ultromics designed EchoGo Amyloidosis to evaluate routine echocardiogram results for signs of cardiac amyloidosis. It received the FDA's breakthrough device designation back in 2023.
cardiovascularbusiness.com
November 29, 2024 at 10:30 AM